Journal article
Lung cancer treatment patterns and factors relating to systemic therapy use in Australia
Preston Ngo, David E Goldsbury, Deme Karikios, Sarsha Yap, Mei Ling Yap, Sam Egger, Dianne L O'Connell, David Ball, Kwun M Fong, Nick Pavlakis, Nicole M Rankin, Shalini Vinod, Karen Canfell, Marianne F Weber
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY | Published : 2021
DOI: 10.1111/ajco.13637
Abstract
AIM: Systemic therapies for lung cancer are rapidly evolving. This study aimed to describe lung cancer treatment patterns in New South Wales, Australia, prior to the introduction of immunotherapy and latest-generation targeted therapies. METHODS: Systemic therapy utilization and treatment-related factors were examined for participants in the New South Wales 45 and Up Study with incident lung cancer ascertained by record linkage to the New South Wales Cancer Registry (2006-2013). Systemic therapy receipt to June 2016 was determined using medical and pharmaceutical claims data from Services Australia, and in-patient hospital records. Factors related to treatment were identified using competing..
View full abstractGrants
Funding Acknowledgements
This research was completed using data collected through the 45 and Up Study (). The 45 and Up Study is managed by the Sax Institute in collaboration with major partner Cancer Council NSW; and partners: the National Heart Foundation of Australia (NSW Division); NSW Ministry of Health; NSW Government Family & Community Services - Ageing, Carers and the Disability Council NSW; and the Australian Red Cross Blood Service. We thank the many thousands of people participating in the 45 and Up Study, the Centre for Health Record Linkage, Services Australia, NSW Ministry of Health, and the Cancer Institute NSW for use of their data. This research was supported by an Australian Government Research Training Program (RTP) Scholarship.